An Algorithmic Approach to Management of Venous Thromboembolism

Research output: Contribution to journalArticle

Abstract

Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to Vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.

Original languageEnglish (US)
Pages (from-to)511-517
Number of pages7
JournalClinical and Applied Thrombosis/Hemostasis
Volume23
Issue number6
DOIs
StatePublished - Sep 1 2017

Fingerprint

Venous Thromboembolism
Pulmonary Embolism
Venous Thrombosis
Hemorrhage
Catheters
Thrombosis
Upper Extremity Deep Vein Thrombosis
Thrombophilia
Vitamin K
Early Detection of Cancer
Anticoagulants
Renal Insufficiency
Veins
Neoplasms
Morbidity
Recurrence
Mortality

Keywords

  • deep venous thrombosis
  • low-molecular-weight heparin
  • new oral anticoagulants
  • pulmonary embolism
  • reversal agents
  • venous thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

An Algorithmic Approach to Management of Venous Thromboembolism. / Dhakal, Prajwal; Gundabolu, Krishna; Bhatt, Vijaya R.

In: Clinical and Applied Thrombosis/Hemostasis, Vol. 23, No. 6, 01.09.2017, p. 511-517.

Research output: Contribution to journalArticle

@article{d44d03206b7949f184795b4bc56a7af8,
title = "An Algorithmic Approach to Management of Venous Thromboembolism",
abstract = "Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to Vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.",
keywords = "deep venous thrombosis, low-molecular-weight heparin, new oral anticoagulants, pulmonary embolism, reversal agents, venous thromboembolism",
author = "Prajwal Dhakal and Krishna Gundabolu and Bhatt, {Vijaya R}",
year = "2017",
month = "9",
day = "1",
doi = "10.1177/1076029616652727",
language = "English (US)",
volume = "23",
pages = "511--517",
journal = "Clinical and Applied Thrombosis/Hemostasis",
issn = "1076-0296",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - An Algorithmic Approach to Management of Venous Thromboembolism

AU - Dhakal, Prajwal

AU - Gundabolu, Krishna

AU - Bhatt, Vijaya R

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to Vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.

AB - Venous thromboembolism (VTE) is associated with significant morbidity and mortality. Factors such as the presence of transient risk factors for VTE, risk of bleeding, and location of deep vein thrombosis (DVT) determine the duration of anticoagulation. Extended anticoagulation is offered to patients with unprovoked pulmonary embolism (PE) or proximal DVT and a low risk of bleeding. Anticoagulation for 3 months is advised in patients with provoked DVT or PE, high risk of bleeding, and isolated distal or upper extremity DVT. In patients with unprovoked PE or proximal DVT and a low risk of bleeding, who want to stop anticoagulation after 3 months, further risk stratification is necessary. Clinical scoring system, and thrombophilia testing otherwise not routinely performed, may be considered to measure risk of annual recurrence in such cases. Short-term anticoagulation may be considered in subsegmental PE and superficial vein thrombosis, particularly if patients are at low risk of bleeding and have persistent risk factors for recurrent VTE. In cases of catheter-associated thrombosis, the catheter need not be removed routinely, and the patient may be anticoagulated for 3 months or longer if the catheter is maintained in patients with cancer. Extensive screening for occult cancer in cases of unprovoked VTE is not beneficial. New oral anticoagulants such as apixaban, rivaroxaban, or dabigatran may be preferred to Vitamin K antagonists in patients without cancer or renal failure, more so after the development of reversal agents such as idarucizumab and andexanet alfa.

KW - deep venous thrombosis

KW - low-molecular-weight heparin

KW - new oral anticoagulants

KW - pulmonary embolism

KW - reversal agents

KW - venous thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=85027547851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027547851&partnerID=8YFLogxK

U2 - 10.1177/1076029616652727

DO - 10.1177/1076029616652727

M3 - Article

VL - 23

SP - 511

EP - 517

JO - Clinical and Applied Thrombosis/Hemostasis

JF - Clinical and Applied Thrombosis/Hemostasis

SN - 1076-0296

IS - 6

ER -